Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical TM solution, a software-as-a-service (SaaS), end-to-end clinical data ...

Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the ...

Life sciences giant Thermo Fisher Scientific has agreed to acquire clinical trials software company Clario for a consideration of up to $9.4bn.

This episode features Dr. Gurmeet Sran, Chief Clinical Data Science Officer at Dignity Health. Here, he discusses his path to Dignity Health, what the newer role of Chief Clinical Data Science Officer ...

The purchase is expected to complement Thermo’s clinical research services, as companies are conducting more trials.

This one-day symposium on Friday, Nov. 14, will convene leaders in neuroscience, clinical research, biomedical engineering, and data science to explore strategies for advancing open and equitable scie ...

Findings indicate that such software can dramatically improve patient safety during surgery. A new study by investigators from Massachusetts General Hospital, a founding member of the Mass General ...

In the early 2000s, Paul Harris, a research informatics faculty member and bioengineer at Vanderbilt University Medical Center, noticed a pressing problem. While working with research teams, he found ...

In the midst of an artificial intelligence boom that’s reshaping almost every facet of the business world, companies are competing in an arms race to build the best and brightest models and fully ...

Thermo Fisher said on Wednesday it would buy privately held data management company Clario for up to $9.4 billion in cash and ...

SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed ...